소아용 백신 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the pediatric vaccines market size was valued at USD 40.24 billion in 2025 and estimated to grow from USD 42.53 billion in 2026 to reach USD 56.06 billion by 2031, at a CAGR of 5.68% during the forecast period (2026-2031).

This report is Segmented by Vaccine Valence (Monovalent and Multivalent), Technology Platform (Live Attenuated, Inactivated, Toxoid, and More), Indication (DTP (Diphtheria-Tetanus-Pertussis), Pneumococcal Disease, and More), Distribution Channel (Public and Private), and Geography (North America, Europe, Asia-Pacific, and More). The Market and Forecasts are Provided in Terms of Value (USD).

Global Pediatric Vaccines Market Trends and Insights

Rising burden of vaccine-preventable diseases & growing immunization awareness

Measles outbreaks underscore widening immunity gaps, with Vietnam recording 81,691 suspected cases in 2025, the highest since 2020 . Similar spikes in pertussis and varicella across parts of Sub-Saharan Africa are prompting emergency catch-up campaigns, driving short-term procurement surges and longer-run commitments to reinforce routine schedules. Influenza mortality among children likewise remains a policy flashpoint, leading national agencies to intensify seasonal vaccination messaging and pivot toward highly immunogenic adjuvanted or cell-based formulations. These epidemiological pressures are stimulating investment in cold-chain upgrades as well as point-of-care digital registries that track individual dose completion and flag drop-outs in real time. Collectively, such measures expand demand for convenience-oriented combination products and encourage accelerated approvals for novel antigens.

Escalating government & NGO funding for pediatric vaccine R&D and procurement

Project NextGen channels USD 5 billion into mucosal and pan-coronavirus candidates poised for pediatric evaluation, signalling long-term federal commitment to transformative prophylaxis. In parallel, Gavi's 2026-2030 strategy seeks at least USD 9 billion in new donor pledges and allocates USD 1.2 billion to the African Vaccine Manufacturing Accelerator to localize production. At the access end, the United States Vaccines for Children Program reliably removes out-of-pocket costs, stabilizing baseline volumes and insulating manufacturers from demand shocks. Such multi-tiered funding frameworks de-risk innovation, shorten payback horizons and help sustain a diversified late-stage pipeline targeting unmet pediatric needs.

High cost of full immunization schedules per child

The CDC now recommends 36 doses before age 2 and more than 70 by age 18, translating into public-sector costs of roughly USD 1,452 and private-sector outlays of USD 2,012 per child according to peer-reviewed analyses. Middle-income economies that recently transitioned out of Gavi support feel the squeeze most acutely, as list prices outpace national purchasing power yet donor assistance winds down. Combination vaccines mitigate some expenditure, but newer platforms such as mRNA still carry premium price tags owing to sophisticated bioprocessing and distribution overheads. Consequently, procurement agencies are piloting outcome-based contracts and pooled advance purchase agreements to preserve coverage levels without breaching budget ceilings.

Other drivers and restraints analyzed in the detailed report include:

1. Rapid adoption of higher-valent/combination vaccines to reduce needle burden
2. Expansion of next-gen platforms (mRNA, VLP, viral-vector) into pediatric profiles
3. Limited healthcare coverage & infrastructure in low- and middle-income countries

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Multivalent formulations captured 61.83% of pediatric vaccines market revenue in 2025, illustrating the clear efficiency gains health systems achieve when several antigens are delivered in one injection. The segment benefits from simplified logistics, reduced clinic visits and improved caregiver acceptance, all of which lower missed-dose rates and contribute to sustained herd immunity.

Demand for monovalent products remains resilient, growing at a 6.35% CAGR through 2031 as niche applications emerge for single-antigen boosters, rapid outbreak control and immunisation of immunocompromised children. Innovations such as MIT's time-release microparticle technology promise to blur the line between single and multi-antigen approaches by packaging separate doses into one shot. As national schedules widen to include maternal RSV and expanded meningococcal protection, the pediatric vaccines market will continue to balance convenience-driven multivalent uptake against targeted monovalent interventions that address specific epidemiological gaps.

Conjugate vaccines maintained a 35.82% revenue lead in 2025, buoyed by two decades of clinical performance against encapsulated bacteria and their inclusion in nearly all first-year schedules. This dominance is unlikely to diminish soon; nevertheless, recombinant technologies are advancing the fastest at 6.31% CAGR as manufacturers exploit high-yield expression systems and scalable bioreactors to meet surging global demand.

The pediatric vaccines market size for recombinant candidates is forecast to expand materially once higher-valent constructs like Sanofi's PCV21 move beyond Phase 3 and enter tender cycles. Concurrently, multivalent mRNA-DTP prototypes illustrate how recombinant and nucleic-acid platforms can cooperate to address waning pertussis immunity. This convergence accelerates portfolio refresh rates and provides mid-tier manufacturers with a cost-effective route into complex antigen markets traditionally controlled by a handful of incumbents.

Complete Report Scope:

• By Vaccine Valence
  • Monovalent
  • Multivalent
• By Technology Platform
  • Live Attenuated
  • Inactivated
  • Toxoid
  • Conjugate
  • Recombinant
  • Others
• By Indication
  • DTP (Diphtheria-Tetanus-Pertussis)
  • Pneumococcal Disease
  • Influenza
  • Measles-Mumps-Rubella (MMR)
  • Others
• By Distribution Channel
  • Public
  • Private
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America controlled 38.72% of global revenue in 2025, buoyed by robust reimbursement systems, stringent school-entry mandates and a continuous stream of FDA approvals such as GSK's 5-in-1 meningococcal shot and Merck's VAXNEUVANCE pediatric indication. The region nonetheless grapples with pockets of hesitancy that threaten coverage thresholds, prompting new digital reminder campaigns and pharmacist-administered programs to keep uptake high. The pediatric vaccines market size in North America is further sustained by Project NextGen funding that lowers technological risk for domestic manufacturers developing multi-pathogen candidates.

Asia-Pacific is forecast to post the highest 6.46% CAGR through 2031. Drivers include large birth cohorts, rising disposable incomes and national rollouts such as India's successful pneumococcal conjugate expansion, which reached 83% booster coverage by 2023. Yet infrastructure gaps and disease resurgence remain pressing challenges; measles surges in Vietnam and neighbouring nations have spurred emergency vaccine stockpiles and fast-track tendering. Regional bodies like APEC have adopted a decade-long plan aiming to vaccinate 23 million children who missed doses during COVID-19 disruptions, signalling persistent momentum for the pediatric vaccines market in fast-growing economies.

Europe retains a sizable share, underpinned by the European Commission's centralised marketing authorisation process that speeds harmonised access. Recent approval of Pfizer's PREVENAR 20 offers the broadest pneumococcal serotype coverage yet for infants and adolescents, cementing conjugate uptake across member states. However, budget ceilings in several economies sharpen the focus on value-based procurement, and reimbursement deliberations are increasingly linked to real-world effectiveness data.

The Middle East & Africa and South America present mixed pictures. Several African Union members leverage Gavi co-financing to build indigenous manufacturing under the African Vaccine Manufacturing Accelerator, while Peru and neighbouring markets work to restore routine childhood coverage lost during the pandemic. Overall, heterogeneous funding and infrastructure will keep growth below the global average, yet targeted donor initiatives, technology transfer agreements and cold-chain modernisation point to gradual improvements in the pediatric vaccines market across these regions.

1. GlaxoSmithKline
2. Pfizer
3. Sanofi
4. Merck
5. AstraZeneca
6. Indian Immunologicals
7. Serum Institute of India
8. Bharat Biotech International Ltd.
9. Biological E Ltd.
10. Mitsubishi Tanabe Pharma Corp.
11. Takeda Pharmaceutical Co.
12. Novavax
13. Moderna
14. Bavarian Nordic
15. SK Bioscience Co., Ltd.
16. Sinovac Biotech
17. Daiichi Sankyo Co., Ltd.
18. Valneva
19. Johnson & Johnson
20. Vaxart, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising burden of vaccine-preventable diseases (VPDs) & growing immunization awareness
  • 4.2.2 Escalating government & NGO funding for pediatric vaccine R&D and procurement
  • 4.2.3 Rapid adoption of higher-valent/combination vaccines to reduce needle burden
  • 4.2.4 Expansion of next-gen platforms (mRNA, VLP, viral-vector) into pediatric profiles
  • 4.2.5 Emergence of maternal & neonatal RSV immunization as a new blockbuster segment
  • 4.2.6 Clinic-level digital supply-chain automation improving pediatric vaccine uptake
• 4.3 Market Restraints
  • 4.3.1 High cost of full immunization schedules per child
  • 4.3.2 Limited healthcare coverage & infrastructure in low- and middle-income countries
  • 4.3.3 Growing vaccine hesitancy and misinformation on pediatric shots
  • 4.3.4 Ultra-cold-chain & last-mile logistics gaps for novel modalities (e.g., mRNA)
• 4.4 Regulatory Landscape
• 4.5 Technological Outlook
• 4.6 Porters Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers/Consumers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitute Products
  • 4.6.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Vaccine Valence
  • 5.1.1 Monovalent
  • 5.1.2 Multivalent
• 5.2 By Technology Platform
  • 5.2.1 Live Attenuated
  • 5.2.2 Inactivated
  • 5.2.3 Toxoid
  • 5.2.4 Conjugate
  • 5.2.5 Recombinant
  • 5.2.6 Others
• 5.3 By Indication
  • 5.3.1 DTP (Diphtheria-Tetanus-Pertussis)
  • 5.3.2 Pneumococcal Disease
  • 5.3.3 Influenza
  • 5.3.4 Measles-Mumps-Rubella (MMR)
  • 5.3.5 Others
• 5.4 By Distribution Channel
  • 5.4.1 Public
  • 5.4.2 Private
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 GlaxoSmithKline plc
  • 6.3.2 Pfizer Inc.
  • 6.3.3 Sanofi SA
  • 6.3.4 Merck & Co., Inc.
  • 6.3.5 AstraZeneca plc
  • 6.3.6 Indian Immunologicals Ltd.
  • 6.3.7 Serum Institute of India Pvt. Ltd.
  • 6.3.8 Bharat Biotech International Ltd.
  • 6.3.9 Biological E Ltd.
  • 6.3.10 Mitsubishi Tanabe Pharma Corp.
  • 6.3.11 Takeda Pharmaceutical Co.
  • 6.3.12 Novavax, Inc.
  • 6.3.13 Moderna, Inc.
  • 6.3.14 Bavarian Nordic A/S
  • 6.3.15 SK Bioscience Co., Ltd.
  • 6.3.16 Sinovac Biotech Ltd.
  • 6.3.17 Daiichi Sankyo Co., Ltd.
  • 6.3.18 Valneva SE
  • 6.3.19 Johnson & Johnson
  • 6.3.20 Vaxart, Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment